AstraZeneca's top-selling cancer drug sees early unblinding in key trial

AstraZeneca Plc said the third phase trial of its top-selling cancer drug Tagrisso, aimed at showing the drug's benefit in lung cancer treatment, will be unblinded early after a recommendation from an independent data monitoring committee.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news